文献速递白血病淋巴瘤

儿童复发难治性T细胞急性淋巴细胞白血病的潜在生物学、挑战与新兴治疗概念

Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2025-08-14

儿童复发难治性T细胞急性淋巴细胞白血病(R/R T-ALL)仍是重大临床挑战,复发或耐药者生存率常低于25%。本文总结儿童T-ALL生物学复杂性及临床转化前景,强调蛋白体抑制剂、BCL-2拮抗剂、JAK/ABL/SRC/MEK/PI3K-mTOR抑制剂、表观遗传药物、免疫治疗(CAR T细胞、生物制剂)及人工智能等新兴治疗路径。

要点

  • R/R T-ALL患儿复发或耐药后生存率常低于25%。
  • T-ALL具遗传、表观遗传、转录后异质性及器官与微环境特异性。
  • 新兴治疗包括蛋白体抑制剂、BCL-2拮抗剂、激酶抑制剂、免疫治疗等。

核心结论

  • R/R T-ALL患儿预后差,生存率常低于25%,需基于生物学特征的个体化精准医学方法改善结局。
  • 针对遗传、表观遗传和转录后异质性的新兴药物与免疫治疗应理性整合入精准医学联合方案。
  • 人工智能和机器学习等新策略可能加速发现并优化治疗框架。

研究设计与样本

  • 本文为综述,总结儿童T-ALL生物学复杂性及临床转化前景。
  • 原文未报告检索范围。

主要发现

  • T-ALL的特征为遗传、表观遗传和转录后异质性,以及器官和微环境特异性(如中枢神经系统)。
  • 儿童复发或对初始治疗耐药者生存率常低于25%。
  • 有前景的新兴方法包括蛋白体抑制剂、BCL-2拮抗剂、JAK抑制剂(用于JAK和IL-7R驱动病例)、ABL和SRC家族酪氨酸激酶抑制剂(用于LCK激活病例)、MEK或PI3K-mTOR抑制剂。
  • MYC靶向药物、DNA去甲基化药物、组蛋白去乙酰化酶抑制剂、剪接调节剂或利用T-ALL代谢弱点的药物是潜在药理学干预的其他例子。
  • 免疫治疗特别是靶向CD7及其他标志物的CAR T细胞产品,以及生物制剂(如靶向CD38)正在开发中且兴趣日增。

临床怎么用

  • 作者认为,应将新兴药物和免疫治疗理性整合入基于遗传、表观遗传和转录后见解的精准医学联合治疗。
  • 作者认为,精准医学联合治疗对完善风险分层和降低耐药风险至关重要。
  • 作者认为,利用人工智能和机器学习的新策略可加速发现并优化治疗框架。
  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed and refractory disease in children with T-cell acute lymphoblastic leukemia (R/R T-ALL) remains a major clinical challenge. Outcomes for children who relapse or exhibit resistance to initial treatments are dismal, with survival rates frequently below 25% despite aggressive therapy. To minimize toxicities and improve outcomes, individualized precision medicine approaches targeting the underlying biology of R/R T-ALL are especially important, considering that T-ALL is characterized by genetic, epigenetic and posttranscriptional heterogeneity, and organ and niche specificities (e.g. the central nervous system), all of which underlie disease progression and therapy resistance. Here, we summarize the current understanding of the complexity of pediatric T-ALL biology and how such knowledge may be clinically leveraged, emphasizing the need for innovative therapeutic routes to improve outcomes for children with R/R T-ALL. Emerging approaches that hold promise or show palpable results include proteasome inhibitors, BCL-2 antagonists, and JAK (for JAK- and IL-7R-driven cases), ABL and SRC family tyrosine kinase (for LCK-activated cases), MEK or PI3K-mTOR inhibitors. MYC-targeting agents, DNA demethylating agents, histone deacetylase inhibitors, splicing modulators, or drugs exploring T-ALL metabolic vulnerabilities, are other examples for potential pharmacological intervention. Immunotherapies, particularly CAR T-cell products targeting CD7 and other markers, but also biologics (e.g. targeting CD38), are under development and increasing interest. These agents should be rationally integrated into precision medicine combination therapies informed by genetic, epigenetic, and posttranscriptional insights that will be essential to refine risk stratification and minimize the risk of resistance. Novel strategies leveraging artificial intelligence and machine learning could accelerate discovery and optimize treatment frameworks.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Amaral P, Christie R, Gresham DOF, et al. Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia. Leukemia. 2025. PMID: 40813621. doi:10.1038/s41375-025-02723-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。